Predicting future cognitive impairment in preclinical Alzheimer’s disease using amyloid PET and MRI: a multisite machine learning study
Authors:
- Braden YangBYBraden Yang
- Tom EarnestTETom Earnest
- Murat BilgelMBMurat Bilgel
- Marilyn S. AlbertMAMarilyn S. Albert
- Sterling C. JohnsonSJSterling C. Johnson
- Christos DavatzikosCDChristos Davatzikos
- Guray ErusGEGuray Erus
- Colin L. MastersCMColin L. Masters
- Susan M. ResnickSRSusan M. Resnick
- Michael I. MillerMMMichael I. Miller
- Arnold BakkerABArnold Bakker
- John C. MorrisJMJohn C. Morris
Preprint
Abstract
Predicting the likelihood of developing Alzheimer’s disease (AD) dementia in at-risk individuals is important for the design of and optimal recruitment for clinical trials of disease-modifying therapies. Machine learning (ML) has been shown to excel in this task; however, there remains a lack of models developed specifically for the preclinical AD population, who display early signs of abnormal brain amyloidosis but remain cognitively unimpaired. Here, we trained and evaluated ML classifiers to predict whether individuals with preclinical AD will progress to mild cognitive impairment or dementia within multiple fixed time windows, ranging from one to five years. Models were trained on regional imaging features extracted from amyloid positron emission tomography and magnetic resonance imaging pooled across seven independent sites and from two amyloid radiotracers ([ 18 F]-florbetapir and [ 11 C]-Pittsburgh-compound-B). Out-of-sample generalizability was evaluated via a leave-one-site-out and leave-one-tracer-out cross-validation. Classifiers achieved an out-of-sample receiver operating characteristic area-under-the-curve of 0.66 or greater when applied to all except one hold-out sites and 0.72 or greater when applied to each hold-out radiotracer. Additionally, when applying our models in a retroactive cohort enrichment analysis on A4 clinical trial data, we observed increased statistical power of detecting differences in amyloid accumulation between placebo and treatment arms after enrichment by ML stratifications. As emerging investigations of new disease-modifying therapies for AD increasingly focus on asymptomatic, preclinical populations, our findings underscore the potential applicability of ML-based patient stratification for recruiting more homogeneous cohorts and improving statistical power for detecting treatment effects for future clinical trials. Highlights: Machine learning can predict future cognitive impairment in preclinical Alzheimer’s Models achieved high out-of-sample ROC-AUC on external sites and PET tracers Models were able to distinguish cognitively stable from decliners in the A4 cohort ML cohort enrichment enhanced secondary treatment effect detection in the A4 cohortKeywords
This publication has 74 references indexed in Scilit:
- Machine learning–enhanced screening funnel for clinical trials in Alzheimer's diseaseAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2025
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association WorkgroupAlzheimer's & Dementia, 2024
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- Natural cubic splines for the analysis of Alzheimer's clinical trialsPharmaceutical Statistics, 2023
- Predictive value of ATN biomarker profiles in estimating disease progression in Alzheimer's disease dementiaAlzheimer's & Dementia, 2021
- Topographical distribution of Aβ predicts progression to dementia in Aβ positive mild cognitive impairmentAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2020
- Staging β-Amyloid Pathology With Amyloid Positron Emission TomographyJAMA Neurology, 2019
- The Preclinical Alzheimer Cognitive CompositeJAMA Neurology, 2014
- Prediction of Cognitive Decline by Positron Emission Tomography of Brain Amyloid and TauArchives of Neurology, 2012
- Tangles and plaques in nondemented aging and ?preclinical? Alzheimer's diseaseAnnals of Neurology, 1999